-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Measurable Residual Disease as an Endpoint in Multiple Myeloma

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
Monday, December 9, 2024, 10:30 AM-12:00 PM

Maryam Sarraf Sarraf Yazdy, MD

(DHM2/CDER), Food and Drug Administration, Silver Spring

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>